Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms
that present many clinical challenges. They secrete peptides and neuroamines that cause …

Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs)
are slowgrowing, median overall survival (OS) in patients with liver metastases is 2 to 4 …

Preliminary Communication Page 1 242 The observed rise in the average doppler frequency
shift was striking. We know that the angle of the ultrasound beam to the vessel in each …

Purpose There are few treatment options for patients with metastasized or inoperable endocrine
gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the response …

The association of height, weight, pubertal stage, calcium intake, and physical activity with
bone mineral density (BMD) was evaluated in 500 children and adolescents (205 boys and …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide versus …

The somatostatin analogue [DOTA 0 ,Tyr 3 ]octreotate has a nine-fold higher affinity for the
somatostatin receptor subtype 2 as compared with [DOTA 0 ,Tyr 3 ]octreotide. Also, labelled …

Fifty patients with somatostatin receptor-positive tumors were treated with multiple doses of [
111 In-diethylenetriamine pentaacetic acid 0 ]octreotide. Forty patients were evaluable after …

Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). …

A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is
the use of radiolabeled somatostatin analogs. Initial studies with high doses of [ 111 In-…